人参皂苷Rg3与TRAIL联合应用对大肠癌细胞株HCE8693作用的实验研究

 目的将人参提取成分20(R)-人参皂苷Rg₃和肿瘤坏死因子(TNF)相关的凋亡诱导配体(TNF-related apoptosis-inducing ligand,TRAIL)基因,联合应用于人大肠癌细胞株HCE8693,来寻求传统中药与现代基因治疗对肿瘤治疗的新途径。方法将人参皂苷Rg₃联合重组腺病毒载体介导的TRAIL基因(Ad／GT-TRAIL)作用于大肠癌细胞株HCE8693。通过MTT比色法与流式细胞仪研究分析其对HCE8693细胞的作用效果。结果 单独应用浓度为0.01％,0.017％,0.025％,0.05％的人参皂苷Rg₃及2000MOI的Ad／GT-TRAIL对HCE8693细胞的生长抑制率分别为8.6％,8.6％,18.7％,21.9％和24.3％;凋亡诱导率分别为5.4％,7.6％,20.3％,20.9％和23.2％。联合应用后,对HCE8693细胞株的生长抑制率及凋亡率均有显著的增强作用,分别达17.8％,25.7％,37.3％,46.2％及18.9％,20.1％,46.2％,56.0％。人参皂苷Rg₃对HCE8693的生长抑制及促凋亡作用存在浓度依赖现象。结论一定浓度的人参皂苷Rg₃或TRAIL能有效抑制HCE8693的生长,人参皂苷Rg₃对HCE8693的生长抑制及促凋亡作用有浓度依赖性。联合应用后,其对HCE8693的生长抑制作用及凋亡诱导作用均明显增强,其协同作用的机制值得进一步探索。

Tumor suppression activity of ginsenoside Rg3 combined with TRAIL gene on human colon cancer cell line HCE8693

OBJECTIVE To find a new way to treat cancer using traditional Chinese medicine and modem gene therapy.The effects of ginsenoside Rg3 and ginsenoside Rg3 combined with TRAIL gene on human colon cancer cell line HCE8693 were evaluated.METHODS Human colon cancer cell line HCE8693 was transfected with adenovirus-mediated TRAIL gene Ad/GT-TRAIL ginsenoside Rg3 combination. Cell growth and apoptosis were measured by MTT method and flow cytometry. RESULTS The cell line HCE8693 was either suppressed by a higher concentration (0.01% ,0.017% ,0.025% ,0.05%) of ginsenoside Rg3 or by TRAIL gene in 2000 MOI. The suppression percentages were 8.6%,8.6%,18.7%,21.9% and24.3% respectively, and the apoptotic percentage were 5.4% ,7.6% ,20.3% ,20.9% and 23.2% respectively. Combined with ginsenoside Rg3 , the suppression and the apoptotic percentage reached 17.8% , 25.7% , 37.3% , 46.2% and 18.9% ,20.1% ,46.2% ,56.0% respectively.CONCLUSIONS A higher concentration of ginsenoside Rg3 or TRAIL gene was able to induce apoptosis and suppress the growth of human colon cancer cell line HCE8693. Ginsenoside Rg3 combined with TRAIL, the suppression and apoptosis could be significantly enhanced. Ginsenoside Rg3 inhibits the growth of HCE8693 and induces apoptosis in a dose-dependent manner.